Compare ANF & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANF | RCUS |
|---|---|---|
| Founded | 1892 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.2B |
| IPO Year | 1996 | 2018 |
| Metric | ANF | RCUS |
|---|---|---|
| Price | $138.05 | $15.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 15 |
| Target Price | ★ $170.64 | $40.92 |
| AVG Volume (30 Days) | 788.5K | ★ 1.9M |
| Earning Date | 11-24-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.59 | N/A |
| Revenue | ★ $5,266,292,000.00 | $247,000,000.00 |
| Revenue This Year | $5.01 | N/A |
| Revenue Next Year | $4.40 | N/A |
| P/E Ratio | $24.62 | ★ N/A |
| Revenue Growth | ★ 6.42 | N/A |
| 52 Week Low | $65.45 | $15.65 |
| 52 Week High | $172.00 | $31.74 |
| Indicator | ANF | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 28.46 |
| Support Level | $130.81 | N/A |
| Resistance Level | $154.90 | $24.80 |
| Average True Range (ATR) | 7.92 | 0.97 |
| MACD | -2.74 | -0.06 |
| Stochastic Oscillator | 5.55 | 1.23 |
Abercrombie & Fitch Co is a digitally led, omnichannel retailer offering apparel, personal care products, and accessories for men, women, and kids through company-owned stores, digital channels, and third-party arrangements. The company operates through three geographic segments: Americas, the maximum revenue generator; Europe, the Middle East and Africa (EMEA); and Asia-Pacific (APAC). Its brand families include Abercrombie brands and Hollister brands. The Americas segment covers North and South America, EMEA includes Europe, the Middle East and Africa, and APAC includes the Asia-Pacific region, including Asia and Oceania.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.